DCLK1 and pachyonychia congenita: In particular, the metabolic characterization of a PC-resistant cell line (GR-Patu8988) generated after treatment with a high dose of gemcitabine indicated that these cells, showing features of CSCs and expressing different EMT markers [165,166], are also characterized by enhanced glycolytic flux and a reduction in intracellular ROS levels, which in turn negatively regulates the expression of doublecortin-like kinase 1 (DCLK1), a newly identified CSC marker critical for the maintenance of stemness and the EMT phenotypes in PC cells [167].